In developed countries, adherence rates for chronic conditions hover around 50% , but for GLP-1 therapies in PCOS, they drop to a mere 27.2% after one year
H.ShuiH
10.1038/s43856-023-00242-8 10 BaliouS.AdamakiM.IoannouP.PappaA.PanayiotidisM
Additionally, it is important to note that weight reduction and improved glycemic control resulting from GLP-1 RA therapy may contribute to the reduction in psoriasis severity [12, 23, 24]
Known for its extended half-life, IGF-1 LR3 remains active in the body for up to 24 hours, allowing for prolonged biological activity
Through targeted stimulation of VEGFR2, BPC-157 promotes vascular runningthe growth of blood vessels toward areas in need of repair ( 4, 5 )